Helene Margaret Finney

This inventor holds 24 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Antibody Therapeutics. Top assignees: Ucb Biopharma Sprl, Ucbbiopharma Srl, Ucb Pharma, S.a.. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Helene Margaret Finney. Retrieved from https://idiyas.com/inventor/helene-margaret-finney

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 5)

% Patents Active = 54.2

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 351(Granted Patents)

Location History:

Maidcnhcad, GB (2006)
Maidenhead, GB (2006 - 2015)
Berkshire, GB (2017)
Slough, GB (2014 - 2023)

Company Filing History:

Celltech Therapeutics Limited

patents

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Anti-FcRn Antibodies

CD22 Binding Molecules

CD45 Binding Molecules

Bispecific Protein Complex

High-Throughput Screening

TNF Alpha Antibodies

Ion Channel Antibodies

Nucleic Acid Production

Synthetic Components

Combinatorial Methods

FcRn Specific Antibodies

CD79 Targeting

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338285 - Anti-FcRn antibodies (2025-06-24),

2. 12331117 - Antibody molecules which bind CD22 (2025-06-17),

3. 11692041 - Antibody molecules which bind CD45 (2023-07-04),

4. 11472879 - Antibody molecules which bind CD22 (2022-10-18),

5. 11384148 - Anti-FcRn antibodies (2022-07-12),

6. 11261252 - Molecules with specificity for CD79 and CD22 (2022-03-01),

7. 11220547 - Antibodies specific to FCRN (2022-01-11),

8. 10954312 - Method employing bispecific protein complex (2021-03-23),

9. 10774152 - Molecules with specificity for CD45 and CD79 (2020-09-15),

10. 10618957 - Antibody molecules which bind CD79 (2020-04-14),

11. 10590197 - Antibody molecules which bind CD22 (2020-03-17),

12. 10370447 - Molecules with specificity for CD79 and CD22 (2019-08-06),

13. 10358493 - Bispecific format suitable for use in high-through-put screening (2019-07-23),

14. 10273302 - Antibodies specific to FcRn (2019-04-30),

15. 10233243 - Anti-FcRn antibodies (2019-03-19),

Title: Innovations in Antibody Molecules: The Contributions of Helene Margaret Finney

Introduction

Helene Margaret Finney is an accomplished inventor based in Slough, GB, known for her significant contributions to the field of biotechnology. With an impressive portfolio of 22 patents, Finney has focused her research on antibody molecules, leading to advancements in therapeutic treatments.

Latest Patents

Two of Finney's latest patents showcase her innovative work in the development of antibody molecules. The first patent relates to constructs comprising a binding domain specific to CD45, detailing pharmaceutical compositions that utilize these constructs for treatment purposes. The second patent addresses antibody molecules that bind to CD22, also emphasizing the potential therapeutic applications through specified binding domains. Both patents reveal her commitment to enhancing medical treatments through biotechnological advancements.

Career Highlights

Throughout her career, Finney has made significant strides in biotechnology while working for notable companies such as UCB Biopharma and UCB Biopharma SRL. Her dedication to research and development is evident in her numerous contributions to scientific literature and patent applications, reflecting a persistent pursuit of innovation in antibody therapies.

Collaborations

Helene Margaret Finney has collaborated with esteemed colleagues, including Alastair David Griffiths Lawson and Kerry Louise Tyson. These partnerships have enriched her research endeavors, leading to impactful developments in the field of immunotherapy and antibody design.

Conclusion

Helene Margaret Finney's work exemplifies the spirit of innovation within the biotechnology sector. With her extensive patent portfolio and collaborative efforts, she continues to influence the future of medical treatments through her groundbreaking inventions in antibody molecules.

Profile summary based on public USPTO records.